with anogenital HPV infection or whether this response confers
Human papillomavirus (HPV) type 16 has been implicated protection against HPV-associated disease. The aim of this study was to characterize CTL activity against the HPV-16 E6 as an etiologic agent in the majority of cases of cervical intraepithelial neoplasia (CIN) and invasive cervical carcinomas [1] .
and E7 proteins in HPV-16-positive women with and without CIN. Immune responses to HPV likely play an important role in controlling HPV infection, as suggested by increased prevalence of HPV-associated disease in patients with HIV-related [1] and iatrogenic immunosuppression [2] .
Materials and Methods

Animal studies suggest a role for an immune response to
Subjects. Nine women from the San Francisco State University the E6 and E7 proteins in protection against HPV-associated Health Center (SFSUHC) and 11 women from the University of disease. Protection from HPV-16 E6-and E7-bearing syngeneic California, San Francisco (UCSF) Dysplasia Clinic were enrolled tumors was inducible in mice immunized with synthetic pepin this study. The SFSUHC subjects were part of a prospective tides [3] or fibroblasts transfected with both the E6 and E7 cohort study followed every 4 months with HPV typing, cytology, proteins [4, 5] as well as in rats inoculated with vaccinia recomand colposcopy for an average of 3.7 years (range, 2.8-4.6) [7] . All binants expressing these proteins [6] . However, little is known had documented previous HPV-16 DNA positivity by polymerase about the cytotoxic T lymphocyte (CTL) response in women chain reaction (PCR) but had never developed biopsy-proven CIN.
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The UCSF women were being treated for newly diagnosed CIN, except for 1 who had recurrent disease.
PCR analysis. PCR analysis was performed using L1 consensus primers and probes as previously described [8] . Cervical, vulvar, anal, and oral swab specimens were obtained from SFSUHC ses revealed no changes from the published sequences. The fusion (Skatron, Sterling, VA), and the 51 Cr disintegrations were counted after 5 h of incubation. Control wells with 51 Cr target cells conproteins were purified using a glutathione agarose affinity column (Sigma, St. Louis). Each preparation was analyzed by SDS-PAGE sisted of spontaneous release (100 mL of assay media without effector cells) and maximum release (100 mL of 5% SDS without and quantified using a protein determination kit (Bio-Rad Laboratories, Richmond, CA). effector cells). Percentage of specific lysis for each effector-totarget cell ratio was calculated as follows: % specific lysis Å Recombinant vaccinia viruses expressing HPV-16 E6 and E7 were constructed to present antigens on target cells in CTL assays. 100 1 [(experimental release 0 spontaneous release)/(maximum release 0 spontaneous release)]. For construction of E6-vac, the plasmid pGEM-2/16-E6 [9] containing the HPV-16 E6 ORF was digested with SalI and KpnI, A positive response was defined as specific lysis 3SD (11%) above the mean of wild type controls at two or more of the four and the released 600-bp fragment was ligated to pSC65 (Moss B, unpublished data). The resulting pSC65/16-E6 plasmid transfer effector-to target-cell ratios.
To determine the specificity of in vitro stimulation, PBMC incuvector contained the E6 ORF regulated by a strong synthetic early/ late vaccinia virus promoter and the lacZ gene regulated by the bated with GST (0.6 mg/mL) and rIL-2, with rIL-2 (20 U/mL) only, and with media only were used in four CTL assays in addition P7.5 early/late vaccinia virus promoter flanked by vaccinia virus thymidine kinase DNA sequences. Cells were infected with the to E6-or E7-stimulated effectors. In seven experiments, PBMC stimulated with E6-GST were incubated with E7-vac-infected tar-WR wild type vaccinia virus strain and transfected with pSC65/ 16-E6. Recombinant E6-vac was isolated by TK selection and get cells and vice versa as additional tests of priming specificity. plaque-purified as described [10] .
The plasmid pGEM-1/16-E7 [9] containing the E7 ORF was digested with PstI, and protruding 3 nucleotides were removed
Results
with T4 DNA polymerase. The linearized plasmid was digested CTL responses to the HPV-16 E6 and E7 proteins were with SmaI, and the resulting 320-bp DNA fragment was ligated studied in 9 subjects without cervical disease and 11 subjects to pSC65 that had been cut with SalI and blunt-ended with the Klenow fragment of DNA polymerase. The plasmid pSC65/16-E7 with CIN (table 1). All 9 women without CIN had prior eviwas used to construct E7-vac as described above. BS-C1 cells dence of HPV-16 infection (4 months to 4 years before the were infected with E6-vac or E7-vac and protein lysates were CTL assay was performed) that resolved spontaneously, except resolved by SDS-PAGE and transferred to a polyvinylidene diflufor subject 18, who had HPV-16 infection 16 months prior to oride membrane (Millipore, Bedford, MA). Western blotting was and on the day blood was drawn for the CTL assay. One HPVperformed using HPV-16/18 E6-specific monoclonal antibodies 16-positive subject (subject 11) had biopsy-confirmed CIN 2, (Oncogene Science, Uniondale, NY) and HPV-16 E7-specific but the pathology report on loop biopsy specimens was normal monoclonal antibodies (Triton Diagnostics, Alameda, CA). Exand this subject was excluded from the data analysis. Of the pression of the E6 and E7 proteins was confirmed (data not shown).
remaining 10 women with CIN, 7 had HPV-16 DNA detected CTL assays. Peripheral blood mononuclear cells (PBMC) were up to 4 months prior to the CTL assay, 2 had unknown HPV isolated from heparinized whole blood (60 mL) using a ficolltype(s), and 1 had HPV 45 and 39/51/52. CTL assays were hypaque (Sigma) density gradient. In a standard assay, effector lymphocytes (10 6 cells/well in 2 mL of medium) were stimulated performed within 3 weeks of loop excision for subjects underfor 7 days with E6-GST or E7-GST (1 mg/mL) in RPMI 1640 going treatment, except for subjects 1 and 4, for whom the with 15% pooled human serum (Norml Cera-Plus; NABI, Miami), assays were performed 3 and 4 months following treatment, penicillin G (100 U/mL), streptomycin (100 mg/mL), gentamicin respectively. (500 mg/mL), and 20 U/mL recombinant interleukin- CTL responses to E6 were detected in 6 (75%) of 8 HPV- are not included for subjects with HPV-16. All samples were collected prior to and at time of CTL assays. Probe mix was used for HPV-t39, -51, and -52.
† Result from paraffin-embedded biopsy specimen. ‡ Specimens that were positive with consensus probe but negative for specific types were classified as having ''unknown'' types. § Subject had CIN 2 on punch biopsy specimen; however, results of subsequent loop excisions were benign. Therefore, she was excluded from CIN group.
x Subject was positive for HPV-16 prior to and at time of CTL assay.
infected with E7-vac and vice versa. Only 2 (29%) of 7 subjects synthetic peptides [12] . In addition, while an earlier study detested exhibited cross-reactivity, as shown in figure 1B . The scribed binding of individual HPV-16 peptides to specific major cross-reactivity was reciprocal in 1 subject (i.e., E6-GST-stimhistocompatibility complex (MHC) haplotypes [13] , our study ulated effectors killed E7-vac-infected targets and vice versa), was designed to measure the CTL response to all possible E6 while it was unilateral (E7-GST stimulated effectors on E6-and E7 epitopes, since full-length proteins were used both for vac infected targets) in the second subject. stimulation and as targets. The proportion of women showing a CTL response to E6 and E7, individually or together, was higher among HPV-16-Discussion positive women without cervical disease than among those with CIN. Although the differences between groups was not Current data suggest that humoral immunity plays only a limstatistically significant due to small sample size, our results ited role in protection against disease once HPV infection is suggest that CTL response to the HPV-16 E6 and E7 proteins established, since seropositivity rates increase with increasing may play a role in protection against development of CIN, grade of cervical disease [11] . To date, there are few data on the consistent with our previous study of the T cell proliferative role of the immune response to HPV proteins in the pathogenesis response to HPV-16 [14] . However, caution is warranted in of CIN. Since earlier animal studies suggested a role for the CTL interpreting these results, since the peripheral CTL response response in tumor protection, we measured CTL activity in HPVmay not correlate with the local immune response. It is also 16-positive women with and without CIN.
possible that the relative lack of CTL responses in women with In this study, autologous transformed B lymphocytes were CIN reflects a suppressive effect of cervical disease on the established from each subject to provide a source of HLAimmune system. matched target cells. This approach permitted the study of all Our current data suggest that a CTL response may persist subjects, including those with rare HLA types, unlike earlier studies of persons with one HLA type using HPV-16-derived after infection, since HPV-16 infection was demonstrated ú1 . In vitro priming with E6-GST is required to demonstrate anti-E6 CTL activity; however, effector cells stimulated with E7-GST cross-react with targets infected with E6-vac. Points represent mean { SE % specific lysis at respective effector:target ratios.
